MARGARET A. TUCKER, M.D.; DAYTON MISFELDT, M.D., Ph.D.; C. NORMAN COLEMAN, M.D.; WALLACE H. CLARK, M.D.; SAUL A. ROSENBERG, M.D.
TUCKER MA, MISFELDT D, COLEMAN CN, CLARK WH, ROSENBERG SA. Cutaneous Malignant Melanoma After Hodgkin's Disease. Ann Intern Med. 1985;102:37-41. doi: 10.7326/0003-4819-102-1-37
Download citation file:
Published: Ann Intern Med. 1985;102(1):37-41.
Eight cutaneous malignant melanomas occurred in 6 of 1405 patients with Hodgkin's disease, although the expected incidence rate was 0.77 (relative risk, 8; 95% confidence interval, 3 to 17). One melanoma was a thin, level II lesion less than 0.76 mm thick; the rest were mostly bulky, deeply invasive lesions despite close clinical surveillance. The melanomas spread aggressively; 3 of 6 patients died within 1 to 3 years. Two of the six patients developed a second primary malignant melanoma 1 year after the first. Two of six patients had biopsy-proven dysplastic nevus syndrome, a known precursor to cutaneous malignant melanoma, and an additional 3 patients had clinical evidence of dysplastic nevus syndrome. Histologically, the malignant melanomas showed a sparse inflammatory infiltrate, an abnormal host response seen previously in cutaneous melanomas developing in immunosuppressed patients. Dysplastic nevi may identify patients at highest risk who require modified medical management.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only